Category Archives: BMY

Bristol-Myers Squibb: Initiating Coverage

Initiating Coverage with an Outperform Rating. Prospects Beyond 2022 are Favorable. With the acquisitions of Celgene in 2019 and MyoKardia in 2020, BMS has substantially transformed its business and repositioned for growth.  Drugs added to the portfolio from the two … Continue reading

Posted in BMY, Health Care | Tagged | Comments Off on Bristol-Myers Squibb: Initiating Coverage